Therefore, we hypothesize that simultaneously suppressing BRAF V600E and ERK1/2 signaling could suppress the re-activation of ERK1/2 signaling by PLX4032, which may likely have a synergistic effect on thyroid gene expression and RAI uptake in thyroid cancer cells with BRAF V600E mutation. The gene discussed is MAPK3; the disease is thyroid gland carcinoma.